LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Primarily to screen for and diagnose acute or chronic hepatitis B virus (HBV) infection, to detect a previous, resolved hepatitis B infection, or sometimes to guide and monitor treatment
When you have risk factors for HBV infection or when you have signs and symptoms of hepatitis, such as jaundice or unexplained elevated blood levels of alanine aminotransferase (ALT), a liver-associated enzyme; when you have a condition that requires chemotherapy or drugs that suppress your immune system; when you are being treated for HBV or hepatitis C (HCV); when it is unclear whether you have immunity and your healthcare practitioner is considering giving you the hepatitis B vaccine
A blood sample drawn from a vein in your arm
Hepatitis B is an infection of the liver caused by the hepatitis B virus (HBV). Hepatitis B blood tests detect viral proteins (antigens), the antibodies that are produced in response to an infection, or detect or evaluate the genetic material (DNA) of the virus. The pattern of test results can identify a person who has a current active infection, was exposed to HBV in the past, or has immunity as a result of vaccination.
For details on the various tests, see the table under Common Questions: How is it used?
Hepatitis is a condition characterized by inflammation and, sometimes, enlargement of the liver. It has various causes, one of which is infection by a virus. HBV is one of five "hepatitis viruses" identified so far that are known to mainly infect the liver. The other four are hepatitis A, hepatitis C, hepatitis D, and hepatitis E.
HBV is spread through contact with blood or other body fluids from an infected person. Exposure can occur, for example, through sharing of needles for IV drug use or through unprotected sex. People who live in or travel to areas of the world where hepatitis B is prevalent are at a greater risk. Mothers who are infected can pass the infection to their babies, usually during or after birth. The virus is not spread through casual contact such as holding hands, coughing or sneezing. However, the virus can survive outside the body for up to seven days, including in dried blood, and can be passed by sharing items such as razors or toothbrushes with an infected person.
Effective hepatitis B vaccines have been available in the U.S. since 1981, and beginning in 1991, healthcare providers in the U.S. began vaccinating infants at birth. Still, the Centers for Disease Control and Prevention (CDC) estimates that between 850,000 and 2.2 million people in the U.S. are chronically infected with the virus, most of whom are not aware that they are infected.
The course of HBV infections can vary from a mild form that lasts only a few weeks to a more serious chronic form lasting years. Sometimes chronic HBV leads to serious complications such as cirrhosis or liver cancer. Some of the various stages or forms of hepatitis B include:
Though a potentially serious infection, acute HBV infection usually resolves on its own in most adults. Infants and children tend to develop a chronic infection more often than adults. Approximately 90% of infants infected with HBV will develop a chronic condition. For children between the ages of one and five, the risk of developing chronic hepatitis drops to between 25% and 50%. Over the age of five, less than 5% of HBV infections become chronic.
The vast majority of those with chronic infections will have no symptoms. For acute infections, the symptoms (when present) are very similar to those of other types of acute hepatitis, although no symptoms occur in over half of those with acute HBV infection. Symptoms include fever, fatigue, nausea, vomiting, and jaundice. With acute hepatitis, the liver is damaged and is not able to function normally. It may not process toxins or waste products such as bilirubin for their removal from the body. During the course of disease, bilirubin and liver enzyme levels in the blood may increase. While tests such as bilirubin or a liver panel can tell a healthcare practitioner that someone has hepatitis, they will not indicate what is causing it. Tests that detect infection with a hepatitis virus may help determine the cause.
The main uses for hepatitis B virus (HBV) tests include:
Some of the secondary reasons to perform testing include: to screen for hepatitis B infection in at-risk populations or in blood donors, to determine if someone is a carrier, to detect a resolved infection, and to determine if immunity has developed due to vaccination.
Generally, one set of tests is used as an initial panel of tests to detect HBV infection or to determine the cause of acute symptoms while another set of tests may be used after a diagnosis is made to monitor possible progression of the disease, to detect chronic infection, and/or to determine carrier status.
The following table summarizes the set of tests typically used for initial testing:
|Test||Description||Use and Comments|
|Hepatitis B surface antigen (HBsAG)||Detects protein that is present on the surface of the virus||To screen for, detect, and help diagnose acute and chronic HBV infections; earliest routine indicator of acute hepatitis B and frequently identifies infected people before symptoms appear; undetectable in the blood during the recovery period; it is the primary way of identifying those with chronic infections, including "HBV carrier" state.|
|Hepatitis B surface antibody (anti-HBs)||Detects antibody produced in response to HBV surface antigen||Used to detect previous exposure to HBV; it can also develop from successful vaccination so it is used to determine the need for vaccination (if anti-HBs is absent) or to determine if a person has recovered from an infection and is immune (cannot get the infection again).|
|Total anti-hepatitis B core (anti-HBc, IgM and IgG)||Detects both IgM and IgG antibodies to hepatitis B core antigen||Can be used to help detect acute and chronic HBV infections; the IgM antibody is the first antibody produced after infection with HBV; IgG antibody is produced in response to the core antigen later in the course of the infection and usually persists for life.|
|Anti-hepatitis B core (anti-HBc, IgM)||Detects only the IgM antibody to the hepatitis B core antigen||Used to detect acute infections; may be included in initial testing, e.g., when done as part of an acute viral hepatitis panel|
The following table summarizes tests that may be used as follow-up after initial tests detect an HBV infection:
|Test||Description||Use and Comments|
|Hepatitis B e-antigen (HBeAG)||Detects protein produced and released into the blood||Often used as a marker of ability to spread the virus to other people (infectivity); it may also be used to monitor the effectiveness of treatment. However, there are some types (strains) of HBV that do not make e-antigen; these are especially common in the Middle East and Asia. In areas where these strains of HBV are common, testing for HBeAg is not very useful to determine whether the virus can be spread to others.|
|Anti-hepatitis B e antibody (Anti-HBe)||Detects antibody produced by the body in response to the hepatitis B "e" antigen||Used to monitor acute infections in those who have recovered from acute hepatitis B infection; anti-HBe will be present along with anti-HBc and anti-HBs.|
|Hepatitis B viral DNA||Detects hepatitis B viral genetic material in the blood||A positive test indicates that the virus is multiplying in a person's body and that person is contagious. The test is often used to monitor the effectiveness of antiviral therapy in people with chronic HBV infections.|
|Hepatitis B virus resistance mutations||Detects mutations in the particular virus causing a person's infection that allows the virus to be resistant to treatments (reverse transcriptase inhibitors)||Helps to select appropriate treatment, especially in people who have been treated previously or in those who are not responding to treatment|
While the tests described above are specific for HBV, other liver tests such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT) may be used to monitor the progress of the disease. In some cases, a liver biopsy may be performed to evaluate how much damage has occurred to the liver.
Hepatitis B tests may be ordered when someone has signs and symptoms associated with acute hepatitis to determine if they are due to infection with HBV. Some of these include:
Hepatitis B tests may be done as follow up when routine tests results such as ALT and/or AST are elevated. Sometimes acute forms of hepatitis may be detected this way since they may cause only mild symptoms that can be confused with the flu. Chronic hepatitis more often has no symptoms and is more commonly detected when routine test results are abnormal.
A test for hepatitis B surface antigen (HBsAg) may be used for screening when someone falls into one of the high-risk categories for chronic hepatitis B. Joint guidelines from the Centers for Disease Control and Prevention (CDC) and American College of Physicians were published in December 2017 and recommend the following groups be tested for HBsAg:
When hepatitis B tests are used to monitor people with chronic hepatitis B infections, they may be performed on a regular basis. Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg), often along with HBV DNA, are usually measured about every 6 months to a year since, in some people, HBeAg (and, less commonly, HBsAg) will go away on their own. In those who are being treated for chronic HBV, HBeAg and HBV DNA tests can be used to determine whether the treatment is successful.
The tests for hepatitis B may be ordered individually but are often ordered in some combination, depending on the reason for testing. Results of the tests are typically evaluated together. Sometimes the meaning of one result depends on the result of another test. However, not all tests are performed for all people.
The table below summarizes possible interpretations of some common patterns of results.
|Initial Tests||Follow-up Tests|
|Hep B surface antigen (HBsAg)||Hep B surface antibody (Anti-HBs)||Hep B core antibody Total (Anti-HBc IgG+IgM)||Hep B core antibody (Anti-HBc IgM)||Hep B e antigen (HBeAg)*||Hep B e antibody (Anti-HBe)||HBV DNA||Possible Interpretation / Stage of Infection|
|Negative||Negative||Negative||Negative||Not performed||Not performed||Not performed||No active or prior infection; not immune — may be good candidate for vaccine; possibly in the incubation stage|
|Negative||Positive||Negative||Not performed||Not performed||Not performed||Not performed||Immunity due to vaccination|
|Negative||Positive||Positive||Not performed||Not performed||Not performed||Not performed||Infection resolved; virus can reactivate if immune system suppressed|
|Positive||Negative||Positive or Negative||Positive||Positive or negative||Negative||Detected||Acute infection, usually with symptoms; contagious; could also be flare of chronic infection|
|Negative||Negative||Positive||Positive||Negative*||Positive||None detected||Acute infection is resolving (convalescent)|
|Positive||Negative||Positive||Negative||Positive* or Negative||Negative or Positive||Detected||Usually indicates an active chronic infection (liver damage likely)|
|Positive||Negative||Positive||Negative||Negative||Positive||None detected or detected at very low level||Chronic infection but low risk of liver damage — carrier state|
*Note: There are some types (strains) of HBV that do not make e-antigen. In areas where these strains of HBV are common (in the Middle East and Asia), testing for HBeAg is not very useful. In these cases, a negative HbeAg result does not necessarily mean that the person is not infectious; it may be that the person is infected with a strain that does not make the e-antigen.
Monitoring treatment of chronic infection: If the results from initial and follow-up testing indicate that a person has chronic hepatitis B, then the individual may be treated with medication and the effectiveness of that treatment may be monitored using the tests for HBe and HBs antigen and antibody and HBV DNA:
Even if you don't have symptoms, an HBV infection can damage your liver and you can spread the infection to others. For this reason, it is important to get tested if you think you have been exposed to HBV.
Blood banks screen all donated blood for the hepatitis B virus (HBV DNA), hepatitis B surface antigen (HbSAg), and hepatitis B core antibody (anti-HBc). Donors are notified of any confirmed positive reactions. People who receive a notice regarding possible infection with hepatitis B after donating should visit their healthcare provider for further testing. The healthcare practitioner will order additional tests to make a proper diagnosis and determine if treatment is necessary.
If exposed to HBV and you haven't been vaccinated, an infection can be avoided by getting a shot of hepatitis B immune globulin (HBIG) within 24 hours and typically you will also be given the first dose of the hepatitis B vaccine.
A test is available to determine the specific type (strain) of hepatitis B virus that is causing a person's infection. This is called HBV genotyping. However, this testing is currently mainly used in research settings and not for clinical purposes.
No. Your healthcare practitioner will determine which test(s) will be appropriate for your symptoms and history.
The Centers for Disease Control and Prevention (CDC) recommends that adults in high-risk groups get vaccinated. Some of these groups include people:
Unless there is something in your medical history to the contrary, it is prudent to get the series of vaccinations. Babies, children and adolescents are routinely given the series of shots; if you have already been vaccinated, you probably are protected for many years, perhaps for life, and will not usually need to get the vaccine again.
There is no specific treatment for acute hepatitis B infections. Symptoms are usually treated with supportive care. This usually involves making sure that you are getting plenty of rest and enough fluids and nutrition by eating and drinking small amounts several times a day.
Chronic forms of hepatitis B may be treated with antiviral medications such as interferon, entecavir, tenofovir, lamivudine, and adefovir. However, some antiviral drugs can have serious side effects and not all people need to be treated. Often, people with chronic hepatitis will be closely monitored to see if they develop cirrhosis or liver cancer. It is important to talk to your healthcare provider about your treatment options and the risks and benefits of those currently available.
Hepatitis D (HDV) is another virus that can cause liver infections, but only if hepatitis B is also present. A person may become infected with both viruses at the same time (a co-infection) or may first be infected with hepatitis B and then become infected with HDV (a superinfection). In the U.S., the incidence of HDV is low. There is no vaccine for HDV, but since it causes infections only in the presence of HBV, it may be prevented with the HBV vaccine.
Sources Used in Current Review
(2018 January 11, Updated). Hepatitis B FAQs for Health Professionals. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#overview. Accessed on 3/18/18.
(2017 November 21, Updated). Testing and Public Health Management of Persons with Chronic Hepatitis B Virus Infection. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/hepatitis/hbv/testingchronic.htm. Accessed on 3/18/18.
Pyrsopoulos, N. and Reddy, K.R. (2017 September 22, Updated). Hepatitis B. Medscape Gastroenterology. Available online at https://emedicine.medscape.com/article/177632-overview. Accessed on 3/18/18.
(2017 May, Updated). Hepatitis B. National Institute of Diabetes and Digestive and Kidney Diseases. Available online at https://www.niddk.nih.gov/health-information/liver-disease/viral-hepatitis/hepatitis-b. Accessed on 3/18/18.
Genzen, J. et. al. (2018 March, Updated). Hepatitis B Virus – HBV. ARUP Consult. Available online at https://arupconsult.com/content/hepatitis-b-virus. Accessed on 3/18/18.
Lal, S. (2015 August 20, Updated). Hepatitis B. MedlinePlus Medical Encyclopedia. Available online at https://medlineplus.gov/ency/article/000279.htm. Accessed on 3/18/18.
(© 1995–2018). Hepatitis B Surface Antigen, Serum. Mayo Clinic Mayo Medical Laboratories. Available online at https://www.mayomedicallaboratories.com/test-catalog/Overview/9013. Accessed on 3/18/18.
Schillie, S. et. al. (2018 January 12). Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention. MMWR, Vol 67,(1);1-31. Available online at https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm. Accessed on 3/24/18.
Sources Used in Previous Reviews
Clinical Chemistry: Principles, Procedures, Correlations. Michael L. Bishop, Janet L. Duben-Engelkirk, Edward P. Fody. Lipincott Williams & Wilkins, 4th Edition.
Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. McPherson RA and Pincus MR, eds. Philadelphia: 2007, Pp 271-272.
Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry. AACC Press, Washington, DC, Pp 273-275, 491-492.
American Association for the Study of Liver Diseases Practice Guidelines, Chronic Hepatitis B: Update 2009. Available online through http://publish.aasld.org. Accessed January 2010.
Centers for Disease Control and Prevention (Reviewed July 8, 2008). Hepatitis B information for Health Professionals. Available online at http://www.cdc.gov/hepatitis/HBV/index.htm. Accessed January 2010.
Centers for Disease Control and Prevention (July 19, 2008). Hepatitis B FAQs for the Public. Available online at http://www.cdc.gov/hepatitis/B/bFAQ.htm#overview. Accessed January 2010.
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE, eds. St. Louis: Elsevier Saunders; 2006, Pp 1805-1806, 1809-1811.
(Revised January 6, 2010) Hepatitis B Foundation. Diagnosis and Management. Available online at http://www.hepb.org/diagnosis/index.htm. Accessed January 2010.
ArupConsult. Hepatitis B Testing and Testing Algorithm. Available online at http://www.arupconsult.com/Topics/InfectiousDz/Viruses/HBV.html# and PDF available for download at http://www.arupconsult.com/Algorithms/HBV.pdf. Accessed January 2010.
MedlinePlus Medical Encyclopedia. Hepatitis B. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/000279.htm. Accessed January 2010.
Centers for Disease Control and Prevention. Hepatitis B Frequently Asked Questions. Available online at http://www.cdc.gov/hepatitis/b/bFAQ.htm#statistics. Accessed August 18, 2013.
Centers for Disease Control and Prevention. Viral Hepatitis Surveillance – U.S., 2010. Available online at http://www.cdc.gov/hepatitis/Statistics/2010Surveillance/Commentary.htm. Accessed August 17, 2013.
Centers for Disease Control and Prevention. 2012. The Pink Book: Course Textbook, 12th edition. Available online at http://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html. Accessed Aug 17, 2013.
Hepatitis B Foundation. Hepatitis B Blood Test FAQ. Available online at http://www.hepb.org/patients/hepatitis_b_blood_tests.htm#ques1. Accessed August 18, 2013.
World Health Organization. Global alert and response. Hepatitis B. Available online at http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index3.html#serologicalmarkers. Accessed Aug 18, 2013.
Fischbach, F.T., (2004) A Manual of Laboratory & Diagnostic Tests. 7th Edition., Lippincott Williams & Wilkins, Philadelphia.
D. Robert Dufour. Viral Hepatitis: Overcoming Diagnostic Challenges. February 2014 Clinical Laboratory News: Volume 40, Number 2. Available online at http://www.aacc.org/publications/cln/2014/february/Pages/Viral-Hepatitis.aspx#. Accessed February 2014.
Henry's Clinical Diagnosis and Management by Laboratory Methods. 22nd ed. McPherson R, Pincus M, eds. Philadelphia, PA: Saunders Elsevier: 2011, Pp 305-307.
©2014 American Red Cross. Learn About Blood, Blood Testing. Available online through http://www.redcrossblood.org. Accessed February 2014.